Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.62 |
| ▸ | POLA1 | P09884 | 1/20 | 0.47 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.42 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.42 |
| ▸ | TYMP | P19971 | 1/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.37 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17279165 | 1.00 | KDM4E (0.62) | KDM4EPOLA1TAS1R3TAS1R1TYMP | |
| SCHEMBL8665070 | 1.00 | KDM4E (0.62) | KDM4EPOLA1TAS1R3TAS1R1TYMP | |
| SCHEMBL16609224 | 0.92 | KDM4E (0.56) | KDM4EPOLA1TAS1R3TAS1R1TYMP | |
| SCHEMBL17279179 | 0.89 | KDM4E (0.54) | KDM4EPOLA1TAS1R3TAS1R1TYMP | |
| SCHEMBL7517850 | 0.89 | KDM4E (0.54) | KDM4EPOLA1TAS1R3TAS1R1TYMP | |
| SCHEMBL16609168 | 0.88 | KDM4E (0.52) | KDM4EPOLA1TAS1R3TAS1R1TYMP | |
| SCHEMBL9343000 | 0.85 | KDM4E (0.57) | KDM4EPOLA1TAS1R3TAS1R1TYMP | |
| SCHEMBL16609179 | 0.84 | KDM4E (0.48) | KDM4EPOLA1TAS1R3TAS1R1TYMP | |
| SCHEMBL8667140 | 0.83 | KDM4E (0.49) | KDM4EPOLA1TAS1R3TAS1R1TYMP | |
| SCHEMBL22702575 | 0.83 | KDM4E (0.49) | KDM4EPOLA1TAS1R3TAS1R1TYMP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4286519-A2 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF MAKING THE SAME | GERON CORPORATION (US) | 2023-12-06 | — | — | EP | disclosed |
| EP-3137479-B1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF MAKING THE SAME | GERON CORP (US) | 2023-08-30 | — | — | EP | disclosed |
| US-11299511-B2 | Oligonucleotide compositions and methods of making the same | GERON CORPORATION (US) | 2022-04-12 | — | — | US | disclosed |
| EP-1543021-A2 | OLIGONUCLEOTIDE CONJUGATES | Geron Corporation (US) | 2005-06-22 | — | — | EP | disclosed |
| EP-1379689-A4 | OLIGONUCLEOTIDE CONJUGATES | GERON CORP (US) | 2004-04-14 | — | — | EP | disclosed |
| WO-2004029277-A2 | OLIGONUCLEOTIDE CONJUGATES | GERON CORPORATION (US) | 2004-04-08 | — | — | WO | disclosed |
| EP-1379689-A2 | OLIGONUCLEOTIDE CONJUGATES | Geron Corporation (US) | 2004-01-14 | — | — | EP | disclosed |
| WO-2002077184-A2 | OLIGONUCLEOTIDE CONJUGATES | GERON CORPORATION (US) | 2002-10-03 | — | — | WO | disclosed |
| EP-0882059-A1 | SOLID PHASE SYNTHESIS OF OLIGONUCLEOTIDE N3-'P5'- PHOSPHORAMIDATES | LYNX THERAPEUTICS, INC. (US) | 1998-12-09 | — | — | EP | disclosed |
| WO-1997031009-A1 | SOLID PHASE SYNTHESIS OF OLIGONUCLEOTIDE N3'→P5' PHOSPHORAMIDATES | LYNX THERAPEUTICS, INC. (US) | 1997-08-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11299511-B2 | Oligonucleotide compositions and methods of making the same | RNGTT, NSUN2, POLN | KDM4E 4575/4885POLA1 26/4885TAS1R3 4567/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.